

10/505244

ATTORNEY DOCKET NO. 21101.0026U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
KUWADA, Scott K.)	Express Mail Label No.
)	EL970614932US
International Application No. PCT/US03/05372)	
)	Date of Deposit:
International Filing Date: 21 February 2003)	August 20, 2004
)	
For: "COMPOSITIONS AND METHODS)	
FOR INHIBITING NF-kB MEDIATED)	
TUMORIGENICITY AND ADHESION-)	
DEPENDENT SURVIVAL OF CANCER)	
CELLS")	

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer No. 23859

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, references listed as A1 – A4 submitted herewith on the accompanying Form PTO 1449 were cited in the International Search Report for the above-referenced international application. In accordance with MPEP 1893.03(g), because the search report was issued by the ISA/US, copies of the documents cited in the international search report should have been made available to the examiner in the international stage application.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(2), in that this Information Disclosure Statement is being filed within

10/505244

ATTORNEY DOCKET NO. 21101.0026U2
International Application No. PCT/US03/05372


three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application.

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

No fee is believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.




David E. Huizenga
Registration No. 49,026

NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300
(678) 420-9301 (fax)

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as Express Mail, Label No. EL970614932US in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.


Michael Laird

Date

8/20/04

90/505244

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF INFORMATION CITED BY APPLICANT (Use as many sheets as necessary)				Complete If Known Intl. Application No. PCT/US03/05372 Intl. Filing Date 21 February 2003 First Named Inventor KUWADA, Scott K. Group Art Unit Unassigned Examiner Name Unassigned	
---	--	--	--	---	--

U.S. PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No

NON-PATENT DOCUMENTS		
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
	A1	Lawrence et al., "Possible New Role for NF-KB in the Resolution of Inflammation", Nature Medicine, December 2001, Vol. 7, pages 1291-1297.
	A2	Maaser et al., "Colonic Epithelial Cells Induce Endothelial Cell Expression of ICAM-1 and V-CAM-1 by a NF-KB-Dependent Mechanism", Clinical Experimental Immunology, 2001, Vol. 124, pages 208-213.
	A3	Catz et al., "Transcriptional Regulation of bcl-2 by Nuclear Factor KB and its Significance in Prostate Cancer", Oncogene, 2001, Vol. 20, pages 7342-7351
	A4	Ni et al., "Analysis of Expression of Nuclear Factor KB (NF-KB) in Multiple Myeloma: Downregulation of NF-KB Induces Apoptosis", British Journal of Haematology, 2001, Vol. 115, pages 279-286.

Examiner Signature:	Date Considered:
---------------------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.